Heyholder
‹ Activism Filings

DONGSUNG PHARMACEUTICAL CO.,LTD Q3 operating loss of KRW 1.7 billion, turning to a loss; sales KRW 19.8 billion

DONGSUNG PHARMACEUTICAL CO.,LTD· Periodic Report

AI summary · Not investment advice

In the third quarter, the company sold KRW 19.8 billion worth of goods and lost KRW 1.7 billion from its main business, down from a profit a year earlier.

Operating profit · 3 months

KRW -1.7 billion

Key facts

Revenue (3 months)
KRW 19.8 billion
Net income (3 months)
KRW -28.0 billion
Period
Q3 (cumulative 2026.01.01 ~ 2026.09.30)
Revenue (prior-year 3 months)
KRW 21.8 billion
Revenue (year to date)
KRW 61.0 billion
Operating profit (prior-year 3 months)
KRW 411.1 million
Operating profit (year to date)
KRW -3.5 billion
Net income (prior-year 3 months)
KRW 112.3 million
Net income (year to date)
KRW -33.9 billion

Commentary

AI commentary · Not investment advice

What happened

Dongsung Pharmaceutical filed its quarterly report for the 3rd quarter of 2026 on a standalone basis. Sales for the latest 3 months were KRW 19.82 billion. That is 9.1% lower than the same 3 months a year earlier (KRW 21.80 billion). It is also 10.3% lower than the previous quarter.

In the company's terms

Operating profit (profit from the core business) for the 3 months was a loss of KRW 1.73 billion. A year earlier it was a profit of KRW 411.4 million. It turned from profit to loss.

What changes for shareholders

Net income (the final profit after all costs and taxes) for the 3 months was a loss of KRW 27.97 billion. A year earlier it was a profit of KRW 112.3 million. It also turned from profit to loss.

For the year to date (Jan 1 to Sep 30), sales were KRW 61.03 billion. Operating profit was a loss of KRW 3.47 billion. Net income was a loss of KRW 33.85 billion.

Comments

No comments yet

Comments from shareholders will appear here.